Skip to main content

Table 2 Treatment outcomes as per-protocol after two-day course of artemisinin-piperaquine [ARPQ, children (n = 30), adults (n = 25)] and a three-day course of artesunate-amodiaquine [ASAQ, children (n = 31), adults (n = 28)] in Vietnamese patients with Plasmodium falciparum malaria

From: The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam

   ARPQ ASAQ P value
Parasite clearance time, median h (IQR)
  All patients 48 (12–72) 36 (24–72) <0.001
  Children 48 (24–72) 36 (24–72) <0.001
  Adults 36 (12–60) 24 (24–48) <0.001
Fever clearance time, median h (IQR)
  All patients 24 (12–48) 12 (12–48) 0.07
  Children 24 (12–48) 12 (12–48) 0.06
  Adults 12 (12–24) 12 (12–48) 0.91
Recrudescence within 42 days, n/N (%)   1/55 (1.8%) 1/59 (1.7%) 0.51
Reinfection within 28 days, n/N (%)   0/55 (0%) 2/59 (3.4%) 0.51
Reinfection within 42 days, n/N (%)   7/55 (12.7%)a, b 9/59 (15.3%)b 0.91
  1. a Mixed infection (Plasmodium falciparum and Plasmodium vivax) was identified in 1 of 7 ARPQ recipients.
  2. bPlasmodium vivax was identified in 3 of 7 recipients for both treatment groups.
  3. IQR - Interquartile range.